Abstract
Iron accumulates progressively in the brain with age; however, the cause is unknown. We hypothesized that iron accumulation may be associated with the age-induced changes in the expression of iron metabolism proteins in the brain. Here, we systematically investigated iron content and the expression of two major iron importers, transferrin receptor 1 (TfR1) and divalent metal transporter (DMT1), two iron exporters, ferroportin 1 (Fpn1) and ceruloplasmin (CP), and hepcidin, along with the pathological hallmarks of Parkinson’s (PD) and Alzheimer’s diseases (AD) in the brain of young (3 months), adult (12 months), and aged (24 months) rats. We demonstrated that age has a region-specific effect on iron transport proteins along with iron content in the cortex, striatum, hippocampus, and substantia nigra. We also found an age-dependent increase in hyperphosphorylated tau, total beta-amyloid, and neurotoxic oligomeric aggregates in the cortex and hippocampus as well as an increase in α-synuclein and a decrease in tyrosine hydroxylase positive neurons in the substantia nigra. Our findings suggest that the age-dependent increase in brain iron may be partly due to the age-induced increase in DMT1 expression, rather than TfR1 and Fpn1 expression, and also imply that the increased brain iron is associated with expression of the pathological hallmarks of AD and PD.
Similar content being viewed by others
References
J.L B, Connor JR, Jones BC (1993) Iron in the brain. Nutr Rev 51:157–170
Levenson CW, Tassabehji NM (2004) Iron and ageing: an introduction to iron regulatory mechanisms. Ageing Res Rev 3:251–263
Gelman BB (1995) Iron in CNS disease. J Neuropathol Exp Neurol 54:477–486
Andrews NC (1999) Disorders of iron metabolism. N Engl J Med 341:1986–1995
Ke Y, Qian ZM (2003) Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol 2:246–253
Núñez MT, Urrutia P, Mena N, Aguirre P, Tapia V, Salazar J (2012) Iron toxicity in neurodegeneration. Biometals 25:761–776
Benkovic SA, Connor JR (1993) Ferritin, transferrin, and iron in selected regions of the adult and aged rat brain. J Comp Neurol 338:97–113
Roskams AJ, Connor JR (1994) Iron, transferrin, and ferritin in the rat brain during development and aging. J Neurochem 63:709–716
Hahn P, Song Y, Ying GS, He X, Beard J, Dunaief JL (2009) Age-dependent and gender-specific changes in mouse tissue iron by strain. Exp Gerontol 44:594–600
Hallgren B, Sourander P (1958) The effect of age on the non-haem in iron in the human brain. J Neurochem 3:41–51
Connor JR, Menzies SL, St Martin SM, Mufson EJ (1992) A histochemical study of iron, transferrin, and ferritin in Alzheimer’s diseased brains. J Neurosci Res 31:75–83
Connor JR, Snyder BS, Beard JL, Fine RE, Mufson EJ (1992) Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer’s disease. J Neurosci Res 31:327–335
Bartzokis G, Sultzer D, Mintz J, Holt LE, Marx P, Phelan CK, Marder SR (1994) In vivo evaluation of brain iron in Alzheimer’s disease and normal subjects using MRI. Biol Psychiat 35:480–487
Bartzokis G, Lu PH, Tishler TA, Peters DG, Kosenko A, Barrall KA, Finn JP, Villablanca P, Laub G, Altshuler LL, Geschwind DH, Mintz J, Neely E, Connor JR (2010) Prevalent iron metabolism gene variants associated with increased brain ferritin iron in healthy older men. J Alzheimers Dis 20:333–341
Zecca L, Gallorini M, Schünemann V, Trautwein AX, Gerlach M, Riederer P, Vezzoni P, Tampellini D (2001) Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem 76:1766–1773
Daugherty A, Raz N (2013) Age-related differences in iron content of subcortical nuclei observed in vivo: a meta-analysis. NeuroImage 70:113–121
Smith MA, Harris PLR, Sayre LM, Perry G (1997) Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A 94:9866–9868
Hirsch EC, Faucheux BA (1998) Iron metabolism and Parkinson’s disease. Mov Disord 13:39–45
Berg D, Gerlach M, Youdim MBH, Double KL, Zecca L, Riederer P, Becker G (2001) Brain iron pathways and their relevance to Parkinson’s disease. J Neurochem 79:225–236
Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5:863–873
Dwyer BE, Zacharski LR, Balestra DJ, Lerner AJ, Perry G, Zhu X, Smith MA (2009) Getting the iron out phlebotomy for Alzheimer’s disease? Med Hypotheses 72:504–509
Qian ZM, Wang Q, Pu YM (1997) Brain iron and neurological disorders. Chin Med J 110:455–458
Qian ZM, Ke Y (2001) Rethinking the role of ceruloplasmin in brain iron metabolism. Brain Res Rev 35:287–294
Lei P, Ayton S, Finkelstein DI, Spoerri L, Ciccotosto GD, Wright DK, Wong BX, Adlard PA, Cherny RA, Lam LQ, Roberts BR, Volitakis I, Egan GF, McLean CA, Cappai R, Duce JA, Bush AI (2012) Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med 18:291–295
Kawas C, Gray S, Brookmeyer R, Fozard J, Zonderman A (2000) Age-specific incidence rates of Alzheimer’s disease: the Baltimore Longitudinal Study of Aging. Neurology 54:2072–2077
Fjell AM, McEvoy L, Holland D, Dale AM, Walhovd KB, Initiative A’s DN (2014) What is normal in normal aging? Effects of aging, amyloid and Alzheimer’s disease on the cerebral cortex and the hippocampus. Prog Neurobiol 117C:20–40
Baldereschi M, Di Carlo A, Rocca WA, Vanni P, Maggi S, Perissinotto E, Grigoletto F, Amaducci L, Inzitari D (2000) Parkinson’s disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 55:1358–1363
Surmeier DJ, Guzman JN, Sanchez J, Schumacker PT (2012) Physiological phenotype and vulnerability in Parkinson’s disease. Cold Spring Harb Perspect Med 2:a009290
Reeve A, Simcox E, Turnbull D (2014) Ageing and Parkinson’s disease: why is advancing age the biggest risk factor? Ageing Res Rev 14C:19–30
Huang XT, Qian ZM, He X, Gong Q, Wu KC, Jiang LR, Lu LN, Zhu ZJ, Zhang HY, Yung WH, Ke Y (2014) Reducing iron in the brain: a novel pharmacologic mechanism of huperzine A in the treatment of Alzheimer’s disease. Neurobiol Aging 35:1045–1054
Qian ZM, Wang Q (1998) Expression of iron transport proteins and excessive iron accumulation in the brain in neurodegenerative disorders. Brain Res Rev 27:257–267
Ke Y, Chang YZ, Duan XL, Du JR, Zhu L, Wang K, Yang X, Ho KP, Qian ZM (2005) Age-dependent and iron-independent expression of two mRNA isoforms of divalent metal transporter 1 in rat brain. Neurobiol Aging 26:739–748
Chang YZ, Qian ZM, Wang K, Zhu L, Yang XD, Du JR, Jiang L, Ho KP, Wang Q, Ke Y (2005) Effects of development and iron status on ceruloplasmin expression in rat brain. J Cell Physiol 204:623–631
Qian ZM, Chang YZ, Zhu L, Yang L, Du JR, Ho KP, Wang Q, Li LZ, Wang CY, Ge X, Jing NL, Li L, Ke Y (2007) Development and iron-dependent expression of hephaestin in different brain regions of rats. J Cell Biochem 102:1225–1233
Qian ZM, Chang YZ, Leung G, Du JR, Zhu L, Wang Q, Niu L, Xu YJ, Yang L, Ho KP, Ke Y (2007) Expression of ferroportin1, hephaestin and ceruloplasmin in rat heart. Biochim Biophys Acta 177:527–532
Wu XM, Qian ZM, Zhu L, Du F, Yung WH, Gong Q, Ke Y (2011) Neuroprotective effect of ligustilide against ischaemia-reperfusion injury via up-regulation of erythropoietin and down-regulation of RTP801. Br J Pharmacol 164:332–343
Jiang DH, Ke Y, Cheng YZ, Ho KP, Qian ZM (2002) Distribution of ferroportin1 protein in different regions of developing rat brain. Dev Neurosci 24:94–98
Ke Y, Qian ZM (2007) Brain iron metabolism: neurobiology and neurochemistry. Prog Neurobiol 83:149–173
Ge XH, Wang Q, Qian ZM, Zhu L, Du F, Yung WH, Yang L, Ke Y (2009) The iron regulatory hormone hepcidin reduces ferroportin 1 content and iron release in H9C2 cardiomyocytes. J Nutr Biochem 20:860–865
Zhao L, Qian ZM, Zhang C, Wing HY, Du F, Ya K (2008) Amyloid beta-peptide 31–35-induced neuronal apoptosis is mediated by caspase-dependent pathways via cAMP-dependent protein kinase A activation. Aging Cell 7:47–57
Maeda J, Zhang MR, Okauchi T, Ji B, Ono M, Hattori S, Kumata K, Iwata N, Saido TC, Trojanowski JQ, Lee VM, Staufenbiel M, Tomiyama T, Mori H, Fukumura T, Suhara T, Higuchi M (2011) In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer’s disease and related disorders. J Neurosci 31:4720–4730
Feany MB, Bender WW (2000) A Drosophila model of Parkinson’s disease. Nature 404:394–398
Chew KC, Ang ET, Tai YK, Tsang F, Lo SQ, Ong E, Ong WY, Shen HM, Lim KL, Dawson VL, Dawson TM, Soong TW (2011) Enhanced autophagy from chronic toxicity of iron and mutant A53T α-synuclein: implications for neuronal cell death in Parkinson disease. J Biol Chem 286:33380–33389
Hagemeier J, Geurts JJ, Zivadinov R (2012) Brain iron accumulation in aging and neurodegenerative disorders. Expert Rev Neurother 12:1467–1480
Focht SJ, Snyder BS, Beard JL, Van Gelder W, Williams LR, Connor JR (1997) Regional distribution of iron, transferrin, ferritin, and oxidatively-modified proteins in young and aged Fischer 344 rat brains. Neuroscience 79:255–261
Dornelles AS, Garcia VA, de Lima MN, Vedana G, Alcalde LA, Bogo MR, Schröder N (2010) mRNA expression of proteins involved in iron homeostasis in brain regions is altered by age and by iron overloading in the neonatal period. Neurochem Res 35:564–571
Thulluri S, Wu M, Blough ER, Manne ND, Litchfield AB, Wang B (2012) Regulation of iron-related molecules in the rat hippocampus: sex- and age-associated differences. Ann Clin Lab Sci 42:145–151
Clardy SL, Wang X, Boyer PJ, Earley CJ, Allen RP, Connor JR (2006) Is ferroportin-hepcidin signaling altered in restless legs syndrome? J Neurol Sci 247:173–179
Zechel S, Huber-Wittmer K, von Bohlen und Halbach O (2006) Distribution of the iron-regulating protein hepcidin in the murine central nervous system. J Neurol Res 84:790–800
Wang Q, Du F, Qian ZM, Ge XH, Zhu L, Yung WH, Yang L, Ke Y (2008) Lipopolysaccharide induces a significant increase in expression of iron regulatory hormone hepcidin in the cortex and substantia nigra in rat brain. Endocrinology 149:3920–3925
Qian ZM, He X, Liang T, Wu KC, Yan YC, Lu LN, Yang G, Luo QQ, Yung WH, Ke Y (2014) Lipopolysaccharides upregulate hepcidin in neuron via microglia and the IL-6/STAT3 signaling pathway. Mol Neurobiol 50(3):811–820
Wang SM, Fu LJ, Duan XL, Crooks DR, Yu P, Qian ZM, Di XJ, Li J, Rouault TA, Chang YZ (2010) Role of hepcidin in murine brain iron metabolism. Cell Mol Life Sci 67:123–133
Du F, Qian C, Qian ZM, Wu XM, Xie H, Yung WH, Ke Y (2011) Hepcidin directly inhibits transferrin receptor 1 expression in astrocytes via a cyclic AMP-protein kinase A pathway. Glia 59:936–945
Nemeth E, Ganz T (2006) Regulation of iron metabolism by hepcidin. Annu Rev Nutr 26:323–342
Martin WR, Ye FQ, Allen PS (1998) Increasing striatal iron content associated with normal aging. Mov Disord 13:281–286
Cass WA, Grondin R, Andersen AH, Zhang Z, Hardy PA, Hussey-Andersen LK, Rayens WS, Gerhardt GA, Gash DM (2007) Iron accumulation in the striatum predicts aging-related decline in motor function in rhesus monkeys. Neurobiol Aging 28:258–271
Raz N, Kennedy KM (2009) A systems approach to the aging brain: neuroanatomic changes, their modifiers, and cognitive correlates. In: Jagust, W., D’Esposito, M. (Eds.), Imaging the aging brain. Oxford University Press, pp. 43–70.
De Domenico I, Zhang TY, Koening CL, Branch RW, London N, Lo E, Daynes RA, Kushner JP, Li D, Ward DM, Kaplan J (2010) Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice. J Clin Invest 120:2395–2405
Ganz T (2011) Hepcidin and iron regulation, 10 years later. Blood 117:4425–4433
Cevenini E, Monti D, Franceschi C (2013) Inflamm-ageing. Curr Opin Clin Nutr Metab Care 16:14–20
Myhre O, Utkilen H, Duale N, Brunborg G, Hofer T (2013) Metal dyshomeostasis and inflammation in Alzheimer’s and Parkinson’s diseases: possible impact of environmental exposures. Oxidative Med Cell Longev 2013:726954
Sadrzadeh SM, Saffari Y (2004) Iron and brain disorders. Am J Clin Pathol 121(Suppl):S64–S70
Chu Y, Kordower JH (2007) Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson’s disease? Neurobiol Dis 25:134–149
Wu M, Katta A, Gadde MK, Liu H, Kakarla SK, Fannin J, Paturi S, Arvapalli RK, Rice KM, Wang Y, Blough ER (2009) Aging associated dysfunction of Akt/protein kinase B: S-nitrosylation and acetaminophen intervention. PLoS One 4:e6430
Wu M, Fannin J, Rice KM, Wang B, Blough ER (2011) Effect of aging on cellular mechanotransduction. Ageing Res Rev 10:1–15
García-Matas S, de Vera N, Aznar AO, Marimon JM, Adell A, Planas AM, Cristòfol R, Sanfeliu C (2010) In vitro and in vivo activation of astrocytes by amyloid-beta is potentiated by pro-oxidant agents. J Alzheimers Dis 20:229–245
Gutteridge JM (1983) Antioxidant properties of caeruloplasmin towards iron- and copper-dependent oxygen radical formation. FEBS Lett 157:37–40
Miyajima H, Takahashi Y, Serizawa M, Kaneko E, Gitlin JD (1996) Increased plasma lipid peroxidation in patients with aceruloplasminemia. Free Rad Biol Med 20:757–760
Qian ZM, Shen X (2001) Brain iron transport and neurodegeneration. Trends Mol Med 7:103–108
Jellinger KA (2004) Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm 111:1219–3125
Li W, Lesuisse C, Xu Y, Troncoso JC, Price DL, Lee MK (2004) Stabilization of alpha-synuclein protein with aging and familial Parkinson’s disease-linked A53T mutation. J Neurosci 24:7400–7409
Mosconi L, Glodzik L, Mistur R, McHugh P, Rich KE, Javier E, Williams S, Pirraglia E, De Santi S, Mehta PD, Zinkowski R, Blennow K, Pratico D, de Leon MJ (2010) Oxidative stress and amyloid-beta pathology in normal individuals with a maternal history of Alzheimer’s. Biol Psychiat 68:913–921
Montine TJ, Peskind ER, Quinn JF, Wilson AM, Montine KS, Galasko D (2011) Increased cerebrospinal fluid F2-isoprostanes are associated with aging and latent Alzheimer’s disease as identified by biomarkers. Neruomol Med 13:37–43
Acknowledgments
The studies in our laboratories were supported by the Competitive Earmarked Grants of The Hong Kong Research Grants Council (GRF14106914, GRF14111815), Hong Kong Health and Medical Research Fund (01120146), and the National Natural Science Foundation of China (NSFC) (31330035, 31271132, 31371092, 31571195).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Author Contributions
Y.K. and Z.M.Q. conceived, organized, and supervised the study; L.N.L. performed the experiments and K.C.W. helped on iron measurement; Y.K. and W.H.Y. contributed to the analysis and interpretation of data; Y.K. and Z.M.Q. prepared and wrote the manuscript.
Conflict of Interest
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Lu, LN., Qian, ZM., Wu, KC. et al. Expression of Iron Transporters and Pathological Hallmarks of Parkinson’s and Alzheimer’s Diseases in the Brain of Young, Adult, and Aged Rats. Mol Neurobiol 54, 5213–5224 (2017). https://doi.org/10.1007/s12035-016-0067-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-016-0067-0